Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin vs Linagliptin for Albuminuria in T2D with Renal Insufficiency
NCT03667300Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Mar 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) and albuminuria (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Percent change of urine albumin-to-creatinine ratio at 24 weeks. Started Mar 2017; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuria
Beyond the preview
Go deeper on NCT03667300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667300.